Clinical Trials Logo

Advanced Ovarian Cancer clinical trials

View clinical trials related to Advanced Ovarian Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03292172 Terminated - Clinical trials for Triple Negative Breast Cancer

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Start date: November 8, 2017
Phase: Phase 1
Study type: Interventional

This is Phase IB, open label, non-randomized study designed to investigate the dose, safety, pharmacokinetics and anti-tumor activity of RO6870810 in combination with a fixed dose of atezolizumab. The study consists of four groups, Group 1 (Dose Escalation Group) and Group 2 (Sequential Dose Group), and Groups 3 and 4 (Expansion Groups), which will further evaluate the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity in patients with triple negaive breast cancer and/or ovarian cancer.